◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Supriya Lifescience Limited (SUPRIYA) Financial History

Name: Supriya Lifescience Limited (SUPRIYA) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-09-20

Supriya Lifescience Limited (SUPRIYA) operates in the Biotechnology industry and is headquartered in Mumbai, India with about 607 employees. Its market capitalization is roughly ₹73 billion. In the fiscal year ended 2026-03-31, SUPRIYA reported ₹8.0B in revenue and ₹2.1B in net income.

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide.

Interactive charts & full statements →

SUPRIYA Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹8.0B	₹6.8B	₹5.6B	₹4.5B	—
Gross Profit	₹4.4B	₹3.9B	₹2.8B	₹2.2B	—
Operating Income (EBIT)	₹2.5B	₹2.4B	₹1.6B	₹1.2B	—
Net Income	₹2.1B	₹1.9B	₹1.2B	₹899M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SUPRIYA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹1.9B	₹2.8B	₹2.1B	₹2.0B	₹1.5B
Gross Profit	₹1.3B	₹1.7B	₹1.5B	₹1.4B	₹1.1B
Operating Income (EBIT)	₹385M	₹891M	₹653M	₹660M	₹452M
Net Income	₹240M	₹742M	₹497M	₹504M	₹348M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SUPRIYA Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(₹80M)	(₹64M)	(₹48M)	(₹48M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SUPRIYA Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹13.6B	₹11.2B	₹9.2B	₹8.2B	—
Total Liabilities	₹1.6B	₹1.2B	₹1.1B	₹1.2B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SUPRIYA viewer.

Other Companies in Biotechnology

1177 · Sino Biopharmaceutical Limited — HK$97 billion
1548 · Genscript Biotech Corporation — HK$90 billion
9926 · Akeso, Inc. — HK$83 billion
REGN · Regeneron Pharmaceuticals — $81 billion
MRNA · Moderna — $61 billion
6821 · Asymchem Laboratories (Tianjin) Co., Ltd. — HK$59 billion
3759 · Pharmaron Beijing Co., Ltd. — HK$54 billion
9995 · RemeGen Co., Ltd. — HK$44 billion

← SUPREMEINF All “S” companies SUPTANERY →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.